Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats.
Time courses of changes in manganese, iron, copper, and zinc concentrations were examined in regions of the brain of a 6-hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease using inductively coupled plasma mass spectrometry (ICP-MS). The concentrations were simultaneously determined in brain section at the level of the substantia nigra 1, 3, 7, 10, 14, and 21 days after the 6-OHDA treatment and compared with those of control rats. The distributions of these elements were obtained for 18 regions of the sagittal section (1-mm thick). The ICP-MS results indicated that Mn, Fe, Cu, and Zn levels of the 6-OHDA-induced parkinsonian brain were observed to increase in all regions that lay along the dopaminergic pathway. In the substantia nigra, the increase in Mn level occurred rapidly from 3 to 7 days and preceded those in the other elements, reaching a plateau in the 6-OHDA brain. Iron and Zn levels increased gradually until 7 days and then increased rapidly from 7 to 10 days. The increase in the copper level was slightly delayed. In other regions, such as the globus pallidus, putamen, and amygdala, the levels of Mn, Fe, Cu, and Zn increased with time after 6-OHDA treatment, although the time courses of their changes were region-specific. These findings contribute to our understanding of the roles of Mn and Fe in the induction of neurological symptoms and progressive loss of dopaminergic neurons in the development of Parkinson's disease. Manganese may hold the key to disturbing cellular Fe homeostasis and accelerating Fe levels, which play the most important role in the development of Parkinson's disease.
Tarohda
Tohru
T
Division of Physical Science, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma, 920-1192, Kanazawa, Japan.
Ishida
Yasushi
Y
Kawai
Keiichi
K
Yamamoto
Masayoshi
M
Amano
Ryohei
R
D018663:Adrenergic Agents / Q000494:pharmacology; D000679:Amygdala / Q000378:metabolism; D000818:Animals; D003300:Copper / Q000378:metabolism*; D005917:Globus Pallidus / Q000378:metabolism; D007501:Iron / Q000378:metabolism*; D008345:Manganese / Q000378:metabolism*; D013058:Mass Spectrometry / Q000379:methods; D016627:Oxidopamine; D010300:Parkinson Disease / Q000209:etiology / Q000378:metabolism*; D011699:Putamen / Q000378:metabolism; D051381:Rats; D013997:Time Factors; D014018:Tissue Distribution; D015032:Zinc / Q000378:metabolism*
D018663:Adrenergic Agents; D008345:Manganese; D003300:Copper; D016627:Oxidopamine; D007501:Iron; D015032:Zinc